NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model
June 26, 2024 — NanoViricides CEO Dr Anil Diwan shares promising news about the company's ultra-broad-spectrum antiviral, NV-387, and its effectiveness in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.